Universus Photo Imagings Limited (UPIL) is a specialized Indian manufacturer and distributor operating at the intersection of medical imaging and durable film technology. Formed through a demerger from **Jindal Poly Films Limited** (effective **April 1, 2019**), the company is currently navigating a strategic pivot. While its legacy business is rooted in analog medical diagnostics, UPIL is aggressively repositioning itself as a diversified healthcare and media solutions provider through significant international investments and R&D-led product innovation. --- ### **Core Business Operations & Product Portfolio** UPIL operates primarily within the **Photo Films** segment, focusing on the conversion, slitting, and distribution of high-quality film products. * **Medical X-Ray Films:** The company procures jumbo rolls and processes them into various sizes. These films remain a staple in semi-urban and rural India due to their cost-effectiveness and independence from complex digital IT infrastructure. * **Non-Tearable (NTR) Films:** A high-margin vertical producing durable films in **Matte & Glossy** finishes. These are utilized for premium photo albums, certificates, playing cards, menu cards, and wedding invitations. * **Manufacturing Infrastructure:** The company operates a specialized facility in **Dadra (UT of Dadra & Nagar Haveli)** with an installed capacity of approximately **300,000 square meters per month**. The plant is equipped with automated monitoring systems and holds **ISO 9001:2015** and **ISO 13485:2016** certifications. --- ### **Strategic Pivot: The MedTech & Healthcare Transition** Recognizing the global shift toward digital radiology, UPIL is transitioning its business model to mitigate the risk of analog obsolescence. * **Market Opportunity:** The company is targeting the Indian medical device market, which is projected to grow from **$14 billion to $30 billion by 2030**. * **Import Substitution:** UPIL is identifying opportunities to manufacture capital equipment domestically (such as **CT and MRI machines**) to reduce India's reliance on imports. * **Digital Integration:** Future growth strategies include the integration of **AI-driven diagnostics** and **digital health platforms** to complement their existing imaging portfolio. * **Geographic Expansion:** To counter shrinking domestic demand for analog films, the company is aggressively targeting export markets in **Africa**. --- ### **Global Investment Architecture: JPF Netherlands B.V.** A substantial portion of UPIL’s enterprise value and strategic direction is tied to its **39.87%** stake in its international associate, **JPF Netherlands B.V. (JPFN)**. * **Global Footprint:** Through JPFN, UPIL maintains indirect interests in imaging and film entities across the **USA, Europe (Belgium, Italy, Germany, Netherlands), Singapore, China, and the UAE**. * **Capitalization of Dividends:** In a major strategic move, UPIL utilized a dividend receivable of **₹174.28 crore** from JPFN to fund a **Rights Issue** subscription. This allowed the company to maintain its stake without a massive cash outflow. * **Recent Capital Commitments:** * **2024-25:** Subscribed to **9,967,500 shares** at **Euro 3 per share**. * **December 2025:** Allotted an additional **3,986,968 shares**. * **Total Investment Value:** Approximately **Euro 29.90 million (~₹270 crores)**, with a net cash remittance of **Euro 9.17 million (~₹83 crores)** after dividend adjustments. --- ### **Financial Performance & Capital Structure** UPIL maintains a stable capital structure characterized by high promoter skin-in-the-game and a reliance on internal accruals. **Standalone Financial Highlights:** | Metric (INR Crore) | FY 2023-24 | FY 2022-23 | | :--- | :---: | :---: | | **Revenue from Operations** | **32.45** | **43.22** | | **Net Profit Before Depreciation & Tax** | **40.49** | **40.23** | | **Net Profit After Tax (PAT)** | **30.89** | **35.01** | **Key Financial Data:** * **Paid-up Equity Capital:** **₹10.95 Crore** (1,09,46,604 shares at **₹10** par value). * **Promoter Holding:** **74.55%**. A significant realignment occurred in **February 2024**, where **67.94%** of the shareholding was transferred to **Concatenate Imaging Advest Private Limited** via an NCLT-sanctioned scheme. * **Foreign Exchange Dynamics:** The company saw a massive surge in foreign exchange earnings in **FY 2024-25**, reaching **₹358.47 crore**, up from **₹76.03 crore** the previous year. However, foreign exchange outgo also remains high at **₹1306.84 crore** due to jumbo roll imports. --- ### **Research, Development & Sustainability** The company’s competitive advantage is sustained through an internal R&D framework focused on "Technology Absorption" rather than external licensing. * **R&D Objectives:** Focus areas include **process optimization**, **application development** (finding new uses for NTR films), and **quality enhancement** to meet evolving customer needs. * **Energy Efficiency:** UPIL is assessing **solar power installations** and has already deployed **LED lighting** and automated utilities to lower the operational cost base. * **Risk Hedging:** The company actively uses **hedging transactions** to manage currency volatility related to the **USD** and **Euro**. --- ### **Risk Factors & Mitigation Strategies** | Risk Category | Description | Mitigation/Status | | :--- | :--- | :--- | | **Market Risk** | Rapid digitalization of X-ray diagnostics. | Diversification into **MedTech** and **NTR films**. | | **Associate Risk** | **JPFN** faced losses of **52,357 (K Euro)** (Dec 2023) due to high European energy costs. | Strategic reinvestment and monitoring of global production volumes. | | **Legal Risk** | Shareholder litigation (Ankit Jain) alleging oppression/mismanagement. | **NCLT Allahabad** dismissed the petition in Oct 2025; currently under appeal at **NCLAT**. | | **Compliance Risk** | Delayed audits of the foreign associate for **FY 23, 24, and 25**. | Use of management-certified unaudited figures for consolidation. | | **Operational Risk** | Pending **Fire NOC** for the Dadra plant (as of late 2023). | Management intent to seek immediate renewal and compliance. | --- ### **Governance & Leadership** The company is led by a stable management team with extended mandates to oversee the current five-year strategic cycle. * **Managing Director:** **Mr. Shailendra Sinha** (Re-appointed until **Dec 2029**). * **Independent Director:** **Mrs. Sonal Agarwal** (Re-appointed until **Dec 2029**). * **Regulatory Standing:** The company is fully compliant with **BSE** and **NSE** listing requirements, with no outstanding fee arrears. All financial reporting follows **Ind-AS** standards.